Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5693238 | 0.86 | PTGS2 (0.57) | PTGS2RIPK1PTGS1KDM4EALDH1A1 | |
| SCHEMBL6225415 | 0.86 | CA1 (0.61) | PTGS2PTGS1KDM4EALDH1A1GLA | |
| SCHEMBL11066334 | 0.82 | RIPK1 (0.50) | RIPK1KDM4EALDH1A1GLAMEN1 | |
| SCHEMBL3679184 | 0.78 | SMN1; SMN2 (0.52) | RIPK1ALDH1A1CA1CA2MEN1 | |
| SCHEMBL27547538 | 0.78 | CA1 (0.45) | RIPK1ALDH1A1CA1CA2 | |
| SCHEMBL7908513 | 0.78 | PTGS2 (0.39) | PTGS2RIPK1PTGS1KDM4EALDH1A1 | |
| SCHEMBL25370685 | 0.78 | MAPT (0.62) | RIPK1ALDH1A1GAACA1CA2 | |
| SCHEMBL14315081 | 0.76 | PTGS2 (0.39) | PTGS2RIPK1PTGS1 | |
| SCHEMBL27556930 | 0.75 | RIPK1 (0.44) | RIPK1ALDH1A1 | |
| SCHEMBL5693406 | 0.74 | PTGS2 (0.76) | PTGS2PTGS1KDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1299682-C | Use of pyrazoline derivatives for the preparation of a medicament for the prevention and/or treatment of cell proliferative diseases | DEL DR ELSTEVE S A LAB (ES) | 2007-02-14 | — | — | CN | claimed |
| EP-1384477-B1 | UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES | ESTEVE LABOR DR (ES) | 2006-05-24 | — | — | EP | claimed |
| CN-1189459-C | Pyrazoline derivatives, process for their preparation and their use as medicaments | ESTEVE LABOR DR (ES) | 2005-02-16 | — | — | CN | claimed |
| CN-1509171-A | Use of pyrazoline derivatives for the preparation of a medicament for the prevention and/or treatment of cell proliferative diseases | ��˹���IJ�ʿʵ���ҹɷ�����˾ | 2004-06-30 | — | — | CN | claimed |
| EP-1083171-B1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2004-04-28 | — | — | EP | claimed |
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-02-19 | — | — | US | claimed |
| EP-1384477-A1 | UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-01-28 | — | — | EP | claimed |
| CN-1307566-A | Pyrazoline derivatives, their prep. and application as medicaments | ESTEVE LABOR DR (ES) | 2001-08-08 | — | — | CN | claimed |
| EP-1083171-A1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | VHL, MET, PRMT1 | PTGS2 3894/4885RIPK1 2959/4885PTGS1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.